Corcept Therapeutics Incorporated NCM · CORT
Price alert —
Sign in to get a one-time email the moment CORT crosses your price. Free accounts included.
Sign in / create a free accountCorcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT last traded at $93.89, up 2.5% on the day; that's in the upper part of its 52-week range ($28.66–$95.11). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.
The next scheduled earnings report (2026-07-30) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
above KC1 lower, +1.57 ATR from EMA21 — no notable pattern
- · Stochastic bull cross
- · Aligned with breakout up (strong tailwind)
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC1 upper stretch — light pop
- · Counter-trend short in breakout up
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Our cash-flow model pegs fair value near $21.86 (fair range $6–$22); today's price sits 320% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Strong. Model estimates only — do your own due diligence.
- ✓ More cash than debt
- ✓ Quick ratio 2.40 (antifragile)
- ✓ Current ratio 2.92 (antifragile)
- ✓ Debt/equity 0.29 (antifragile)
- ⚠ Stock comp 11% of revenue (heavy dilution)
Price implies ~32% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
CORT is a $9.8 billion company, priced at 254× last year's earnings, and it moves more calmly than the market (beta 0.5); the stock is trading near the top of its 52-week range.
Options idea
See more →Earnings
See more →- Last reported
- 2026-04-30
- EPS (act / est)
- -0.30 / -0.14
- Surprise
- -111.3%
- Next report
- 2026-07-30
About
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's synd…